(68 days)
No
The summary describes automated analysis software for flow cytometry data, but there is no mention of AI, ML, or related terms. The analysis appears to be based on predefined gating and enumeration methods common in flow cytometry.
No
The device is described as an automated analysis method for simultaneous identification and enumeration of lymphocyte subpopulations, intended "For In Vitro Diagnostic Use". It does not describe any direct therapeutic action or treatment.
Yes
The "Intended Use / Indications for Use" section explicitly states that the system is intended "For In Vitro Diagnostic Use," allowing for the identification and enumeration of various lymphocyte populations, which is a diagnostic purpose.
No
The device description explicitly states that the system "consists of... monoclonal antibody reagents, quality control reagents, an optional absolute count reagent, and automated application and operating software on the Cytomics FC 500 Flow Cytometer." This indicates the device includes hardware components (reagents and the flow cytometer) in addition to the software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section explicitly states that the system with the specified reagents is intended "For In Vitro Diagnostic Use".
- Nature of the Test: The device analyzes components of whole blood (lymphocyte subpopulations) using reagents and software. This is a classic example of an in vitro diagnostic test, performed outside the body on a biological sample to provide information for diagnosis or monitoring.
N/A
Intended Use / Indications for Use
The tetraCXP SYSTEM for the Cytomics FC 500 flow cytometry systems is an automated analysis method for simultaneous identification and enumeration of lymphocyte subpopulations (CD3+, CD4+, CD8+, CD19+and CD56+) combining four-color fluorescent monoclonal antibody reagents, quality control reagents, optional absolute count reagent and CXP software. The system with CYTO-STAT tetraCHROME CD45-FITC/CD4-PE/CD8-ECD/CD3-PC5 Monoclonal antibody reagent is intended "For In Vitro Diagnostic Use", allowing the identification and enumeration of Total CD3+ (T cells), Total CD4+, Total CD8+, Dual CD3+/CD4+, Dual CD3+/CD8+ lymphocyte percentages and absolute counts as well as the CD4/CD8 ratio in whole blood flow cytometry. The system with CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5, the total lymphocyte percentage can be obtained. CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5 monoclonal antibody reagent is intended "For In Vitro Diagnostic Use", allowing the identification and enumeration of total CD19+ (B cells) and CD3-/CD56+ (NK cells) lymphocyte percentages and absolute counts in whole blood flow cytometry. The total lymphocyte percentage can be obtained as well.
The tetraCXP Software for Cytomics FC 500 flow cytometry systems and CYTO-STAT tetraCHROME™ CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 and CYTO-STAT tetraCHROME™ CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 Monoclonal Antibody Reagents combine four-color fluorescent monoclonal antibody reagents, quality control reagents, an optional absolute count reagent, and software for automated analysis of lymphocyte populations in whole blood using Cytomics FC 500 flow cytometry systems with CXP Software.
The system with CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 is intended "For In Vitro Diagnostic Use" and allows simultaneous identification and enumeration of total CD3+, total CD4+, total CD8+, dual CD3+/CD4+ and dual CD3+/CD8+ T lymphocyte population percentages and absolute counts.
The system with CYTO-STAT tetraCHROME CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 is intended "For In Vitro Diagnostic Use" and allows simultaneous identification and enumeration of total CD3+ (T), CD19+ (B), and CD3-/CD56+ (NK) lymphocyte population percentages and absolute counts. This reagent reflects the distribution of the three major subsets comprising the lymphocyte population upon which other lymphocyte enumeration studies are based and provides the total lymphocyte percentage.
Product codes
GKZ
Device Description
tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software consists of CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 and CYTO-STAT tetraCHROME CD-45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 monoclonal antibody reagents, quality control reagents, an optional absolute count reagent, and automated application and operating software on the Cytomics FC 500 Flow Cytometer.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 864.5220 Automated differential cell counter.
(a)
Identification. An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.(b)
Classification. Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”
0
510(k) Summary of Safety and Effectiveness for Section 1 D:
tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software
| 1.0 | General Information |
|---|---|
| Applicant Name and Address: | Beckman Coulter, Inc. |
| Cellular Analysis Division | |
| 11800 SW 147 Avenue | |
| Miami, FL 33196-2500 | |
| Primary Contact: | Stan Sugrue, Ph.D. |
| Senior Regulatory Affairs Specialist | |
| Telephone: (305) 380-4552 | |
| FAX: (305) 380-3618 | |
| E-mail: stan.sugrue@coulter.com | |
| Date: | March 13, 2003 |
| Device Trade Name(s): | tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software |
| Device Generic Name(s): | Automated differential cell counter |
| Device Classification: | The tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software is a Class II medical device |
2.0 Predicate Device
The tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software claims substantial equivalence to the tetraONE SYSTEM for EPICS XL Flow Cytometry SYSTEM with CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 Monoclonal Antibody Reagent and CYTO-STAT tetraCHROME CD-45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 Monoclonal Antibody Reagent.
FDA 510(k) Number(s): K990172
3.0 Device Description
tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software consists of CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 and CYTO-STAT tetraCHROME CD-45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 monoclonal antibody reagents, quality control reagents, an optional absolute count reagent, and automated application and operating software on the Cytomics FC 500 Flow Cytometer.
4.0 Principle of Method:
This test depends upon the ability of an monoclonal antibody to bind to the surface of cells expressing discrete antigenic determinants. Specific cell staining is accomplished by incubating whole blood with monoclonal antibody reagent. Red blood cells are lysed and the remaining white cells are analyzed on the FC 500 flow cytometry systems with CXP software and the tetraCXP SYSTEM (reagent application) software packages. The tetraCXP SYSTEM reagent application software, in conjunction with CXP operating system software on the FC 500 flow cytometer, tetraCHROME monoclonal antibody reagents, provides automated analysis of lymphocyte subpopulations.
1
5 0 Comparison to Predicate
| Comparison | Characteristic | tetraONE System
(Predicate) | tetraCXP System |
|--------------|---------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------|
| Similarities | Intended Use | Enumeration of total T, B, and NK lymphocytes and three major lymphocyte subset populations | Same as tetraONE |
| | Analysis Reagents | CYTO-STAT®
tetraCHROME™ CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 | Same as tetraONE |
| | | CYTO-STAT®
tetraCHROME™ CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5
Flow-Count™ Fluorospheres | |
| | AutoSetup Reagents | Flow-Set™ Fluorospheres
CYTO-COMP™ Cell Kit | Same as tetraONE |
| | QC Reagents | CYTO-TROL™ Control Cells or
IMMUNO-TROL™ Cells
IMMUNO-TROL™ Low Cells | Same as tetraONE |
| | Automated Analysis
Algorithm | cellSTAT 3D™ algorithm | Based on cellSTAT 3D™
algorithm |
| Differences | Flow Cytometer | EPICS® XL-MCL™ flow
cytometry system | CYTOMICS FC 500 flow
cytometry system |
| | System Software | System II | CXP |
| | AutoSetup Reagents | CYTO-COMP™
Reagent Kit | QuickCOMP 4 Kit |
6.0 Indications for Use:
The tetraCXP SYSTEM for the Cytomics FC 500 flow cytometry systems is an automated analysis method for simultaneous identification and enumeration of lymphocyte subpopulations (CD3+, CD4+, CD8+, CD19+and CD56+) combining four-color fluorescent monoclonal antibody reagents, quality control reagents, optional absolute count reagent and CXP software. The system with CYTO-STAT tetraCHROME CD45-FITC/CD4-PE/CD8-ECD/CD3-PC5 Monoclonal antibody reagent is intended "For In Vitro Diagnostic Use", allowing the identification and enumeration of Total CD3+ (T cells), Total CD4+, Total CD8+, Dual CD3+/CD4+, Dual CD3+/CD8+ lymphocyte percentages and absolute counts as well as the CD4/CD8 ratio in whole blood flow cytometry. The system with CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5, the total lymphocyte percentage can be obtained. CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5 monoclonal antibody reagent is intended "For In Vitro Diagnostic Use", allowing the identification and enumeration of total CD19+ (B cells) and CD3-/CD56+ (NK cells) lymphocyte percentages and absolute counts in whole blood flow cytometry. The total lymphocyte percentage can be obtained as well,
7.0 Conclusion:
The tetraCXP SYSTEM for the Cytomics FC 500 flow cytometry systems is substantially equivalent to the previously cleared tetraONE System for EPICS XL Flow Cytometry System with CYTO-STAT® tetraCHROME™ CD45-FITC/CD4-PE/CD8-ECD/CD3-PC5 Monoclonal Antibody Reagent and CYTO-STAT® tetraCHROME™ CD45-FITC/CD56-PE/CD19-ECD/CD3-PC5 Monoclonal Antibody Reagent.
2
Section 1 F:
Submitted By 1.0
Beckman Coulter, Inc. Cellular Analysis Division 11800 SW 147 Avenue Miami, FL 33196-2500
Primary Contact: Stan Sugrue, Ph.D. Senior Regulatory Affairs Specialist Telephone: (305) 380-4552 FAX: (305) 380-3618 E-mail: stan.sugrue@coulter.com
Secondary Contact: Deborah Herrera Group Manager, Requlatory Affairs Telephone: (305) 380-4013 FAX: (305) 380-3618 E-mail: debbie.herrera@coulter.com
2.0 Sponsor Address/FDA Registration Number
Beckman Coulter, Inc. Cytomics Division 11800 SW 147 Avenue Miami. FL 33196-2500 FDA Establishment Registration: 1061932
3.0 Device Name(s)/Classification Name and Number
Device Trade Name(s): tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software
Classification Name and Number: Automated differential cell counter : 21 CFR 864.5220
4.0 Device Classification
The Hematology Panel has classified Automated differential cell counters as Class II, (81 GKZ) devices.
Section 514 Compliance 5.0
This Abbreviated 510(k) submission is prepared in accordance with FDA publication : The New 510(k) Paradigm: Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications-Issue Date: March 20, 1998. It claims compliance with the FDA publication: Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood cells; Final Guidance for Industry and FDA- Issue Date: December 4, 2001.
3
Image /page/3/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services USA. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines suggesting movement or connection.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Stan Sugrue, Ph.D. Senior Regulatory Affairs Specialist Beckman Coulter, Inc. Cellular Analysis Division 11800 SW 147 Avenue Miami. Florida 33196-2500
MAY 21 2003
Re: K030828
Trade/Device Name: tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software Regulation Number: 21 CFR § 864.5220 Regulation Name: Automated differential cell counter Regulatory Class: II Product Code: GKZ Dated: March 13, 2003 Received: March 14, 2003
Dear Dr. Sugrue:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
4
Page 2 –
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
Section 1C:
INDICATIONS FOR USE
K030828
510(k) Number (if known): Not assigned
Device:
tetraCXP SYSTEM for the Cytomics FC 500 with CXP Software
The tetraCXP Software for Cytomics FC 500 flow cytometry systems and CYTO-STAT tetraCHROME™ CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 and CYTO-STAT tetraCHROME™ CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 Monoclonal Antibody Reagents combine four-color fluorescent monoclonal antibody reagents, quality control reagents, an optional absolute count reagent, and software for automated analysis of lymphocyte populations in whole blood using Cytomics FC 500 flow cytometry systems with CXP Software.
The system with CYTO-STAT tetraCHROME CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 is intended "For In Vitro Diagnostic Use" and allows simultaneous identification and enumeration of total CD3+, total CD4+, total CD8+, dual CD3+/CD4+ and dual CD3+/CD8+ T lymphocyte population percentages and absolute counts.
The system with CYTO-STAT tetraCHROME CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 is intended "For In Vitro Diagnostic Use" and allows simultaneous identification and enumeration of total CD3+ (T), CD19+ (B), and CD3-/CD56+ (NK) lymphocyte population percentages and absolute counts. This reagent reflects the distribution of the three major subsets comprising the lymphocyte population upon which other lymphocyte enumeration studies are based and provides the total lymphocyte percentage.
21 CFR 864.5220 Automated differential cell counter
An automated differential cell counter is a device used to identify and classify one or more of the formed elements of blood.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use " Use (Per 21 CFR 801.109)
OR
Over-The-Counter
Rosalina Bautista
| (Division Sign-Off) | |
|---|---|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K0 30828 |
Beckman Coulter, Inc. tetra CXP SYSTEM